TY  - GEN
AU  - Johnson,Margaret
AU  - Kumar,Princy
AU  - Molina,Jean-Michel
AU  - Rizzardini,Giuliano
AU  - Cahn,Pedro
AU  - Bickel,Markus
AU  - Mallolas,Josep
AU  - Zhou,Yan
AU  - Morais,Cristiana
AU  - Kumar,Sushma
AU  - Sklar,Peter
AU  - Hanna,George J
AU  - Hwang,Carey
AU  - Greaves,Wayne
TI  - Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
SN  - 1944-7884
PY  - 2020///0218
KW  - Adult
KW  - Aged
KW  - Anti-Retroviral Agents
KW  - administration & dosage
KW  - Equivalence Trials as Topic
KW  - Female
KW  - HIV-1
KW  - drug effects
KW  - Humans
KW  - Lamivudine
KW  - Male
KW  - Middle Aged
KW  - Protease Inhibitors
KW  - therapeutic use
KW  - Pyridones
KW  - Quinolones
KW  - Ritonavir
KW  - Tenofovir
KW  - Treatment Outcome
KW  - Triazoles
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/QAI.0000000000002056
ER  -